GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cell Source CLCS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.40

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cell Source

From its filings with the US Securities and Exchange Commission

SEC filings

Cell Source is based in New York, New York and is incorporated in Nevada. Its shares trade on OTC under the ticker CLCS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported a net loss of $4.5m. At that date it held total assets of $286,500 and shareholders' equity of −$18.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
14 Jan 2014
Head office
57 WEST 57TH STREET, NEW YORK, NY, 10019
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Dennis BrownIndependent Chairman of the Board, since 2014$44,400
  • Mr. Itamar ShimratChief Executive Officer, Chief Financial Officer, Director, since 2014$204,290
  • Ms. Darlene SoaveDirector$37,300
  • Mr. George VerstraeteDirector$37,300

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cell Source Inc's Veto Cell technology enables selective blocking of immune responses in allogeneic HSCT.
  • Veto Cell technology shows promising results in haploidentical stem cell transplants with mild conditioning.
  • Cell Source Limited is a wholly owned subsidiary developing immune system management solutions.

Weaknesses

  • Veto Cell technology remains in pre-clinical phase without approved products.
  • The company has no revenue from commercialized products as of 2024.
  • Cell Source Inc's IPO occurred in 2014 with no recent market expansion.

Opportunities

  • VETO CAR-T therapies target B-cell malignancies and solid tumors for growth opportunities.
  • Veto Cell kidney and liver transplants could expand into new medical segments.
  • Veto HSCT for non-malignant disorders presents a new market segment.

Threats

  • Veto Cell technology faces competition from established biotech firms in immunotherapy.
  • Regulatory approval delays could impact VETO CAR-T therapy development timelines.
  • The pre-clinical stage of Veto Cell technology poses development risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.